Trial Profile
Evaluation of the Efficacy and Tolerance of Fractionated Radio-immunotherapy With 90Y-Epratuzumab (90Y-hLL2) for Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Epratuzumab Y-90 (Primary) ; Epratuzumab
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 18 May 2011 New trial record